EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Edwards Lifesciences Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $50.38B
- P/E (TTM)
- 50.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.0%
524M of 576M shares
Institutional holders
1,330
164 new, 101 sold out
Net institutional buying
21M
In Q2 2026
Insider trades, 12 months
0 buys · 53 sales
Net sold $27.68M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 44,267,376 | 7.50% | 13G (passive) amendment | Sep 30, 2025 |
| Vanguard Capital Management | 43,477,533 | 7.54% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 58,789,433 | 10.20% | $5.32B | +6,198,500 | 0.08% |
| Vanguard Capital Management LLC | 37,615,952 | 6.53% | $3.40B | −111,840 | 0.07% |
| Vanguard Portfolio Management LLC | 26,411,402 | 4.58% | $2.39B | +4,384 | 0.11% |
| State Street Corp | 26,321,940 | 4.57% | $2.38B | +25,541 | 0.07% |
| JPMorgan Chase & Co | 22,783,175 | 3.95% | $2.08B | +1,038,463 | 0.11% |
| Wellington Management Group Llp | 16,827,967 | 2.92% | $1.52B | −5,183,134 | 0.26% |
| Geode Capital Management, LLC | 15,437,251 | 2.68% | $1.39B | +2,303,474 | 0.07% |
| Bank of New York Mellon Corp | 14,084,483 | 2.44% | $1.27B | −2,653,065 | 0.21% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 13,002,965 | 2.26% | $1.18B | +191,063 | 0.90% |
| Ninety One UK Ltd | 12,337,502 | 2.14% | $1.12B | −58,641 | 2.50% |
| Aristotle Capital Management, LLC | 8,665,712 | 1.50% | $783.91M | New | 1.64% |
| Alliancebernstein L.P. | 8,660,416 | 1.50% | $693.53M | +5,193,061 | 0.23% |
| FMR LLC | 8,435,949 | 1.46% | $763.12M | −6,067,821 | 0.03% |
| Norges Bank | 8,373,783 | 1.45% | $757.49M | New | 0.08% |
| Brown Advisory Inc | 7,365,987 | 1.28% | $666.33M | +336,475 | 1.03% |
| Bank Of America Corp /De/ | 6,692,424 | 1.16% | $605.40M | +2,809,005 | 0.04% |
| Artisan Partners Limited Partnership | 6,625,703 | 1.15% | $599.36M | +1,424,559 | 0.95% |
| Morgan Stanley | 6,339,368 | 1.10% | $573.46M | −721,508 | 0.03% |
| Deutsche Bank AG\ | 5,710,284 | 0.99% | $516.55M | −344,739 | 0.15% |
| Arrowstreet Capital, Limited Partnership | 5,677,344 | 0.98% | $513.57M | +3,786,485 | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,330 | 524M | 91.0% | 164 / 469 | 466 / 101 | 70M | 48M |
| Q1 2026 | 1,290 | 504M | 87.5% | 113 / 456 | 459 / 119 | 118M | 51M |
| Q4 2025 | 1,315 | 507M | 88.0% | 186 / 423 | 476 / 100 | 46M | 61M |
| Q3 2025 | 1,254 | 525M | 91.2% | 114 / 446 | 441 / 106 | 74M | 54M |
| Q2 2025 | 1,259 | 506M | 87.8% | 164 / 421 | 459 / 94 | 49M | 48M |
| Q1 2025 | 1,206 | 506M | 87.8% | 124 / 387 | 487 / 122 | 46M | 39M |
| Q4 2024 | 1,226 | 503M | 87.3% | 191 / 352 | 501 / 141 | 66M | 50M |
| Q3 2024 | 1,195 | 491M | 85.2% | 142 / 371 | 498 / 227 | 125M | 86M |
| Q2 2024 | 1,296 | 503M | 87.3% | 123 / 461 | 467 / 91 | 30M | 35M |
| Q1 2024 | 1,278 | 512M | 88.8% | 161 / 432 | 462 / 109 | 53M | 40M |
| Q4 2023 | 1,245 | 499M | 86.5% | 173 / 378 | 500 / 132 | 62M | 54M |
| Q3 2023 | 1,221 | 493M | 85.5% | 108 / 432 | 465 / 152 | 38M | 40M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EW | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 18,279,615 | 3.17% | $1.65B | 0.07% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 14,919,502 | 2.59% | $1.35B | 0.08% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 12,476,018 | 2.16% | $1.13B | 0.50% | Jun 30, 2026 |
| Vanguard Health Care Fund | 11,357,910 | 1.97% | $977.58M | 2.56% | Jul 31, 2026 |
| iShares Core S&P 500 ETF | 7,920,729 | 1.37% | $716.51M | 0.08% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 7,426,109 | 1.29% | $642.14M | 0.08% | May 31, 2026 |
| Vanguard Value Index Fund | 5,475,762 | 0.95% | $495.34M | 0.19% | Jun 30, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 4,411,246 | 0.77% | $399.04M | 1.15% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 4,067,877 | 0.71% | $367.98M | 0.91% | Jun 30, 2026 |
| JPMorgan U.S. Equity Fund | 3,216,213 | 0.56% | $290.94M | 0.87% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 3,125,977 | 0.54% | $282.78M | 0.08% | Jun 30, 2026 |
| Vanguard Windsor Ii Fund | 3,121,221 | 0.54% | $268.64M | 0.40% | Jul 31, 2026 |
| iShares Russell Mid-Cap ETF | 2,343,629 | 0.41% | $212.00M | 0.37% | Jun 30, 2026 |
| Fidelity Mid Cap Index Fund | 2,174,871 | 0.38% | $187.19M | 0.36% | Jul 31, 2026 |
| Invesco S&P 500 Equal Weight ETF | 2,167,082 | 0.38% | $186.52M | 0.19% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bernard J. Zovighian | CEO, Director | 123,330 | 0.02% | Jul 27, 2026 |
| Andrew M. Dahl | SVP, Corporate Controller | 14,615 | 0.00% | Sep 14, 2026 |
| Wayne Markowitz | CVP, JAPAC | 19,371 | 0.00% | Sep 14, 2026 |
| Daveen Chopra | CVP, TMTT, Surgical & IHFM | 43,926 | 0.01% | Sep 11, 2026 |
| Daniel J. Lippis | CVP, TAVR | 40,034 | 0.01% | Sep 11, 2026 |
| Annette Bruls | CVP, EMEACLA | 17,984 | 0.00% | Aug 28, 2026 |
| Theodora Mistras | CVP, Chief Financial Officer | 87,595 | 0.02% | Jul 10, 2026 |
| Donald E. Bobo Jr | CVP,Strategy/Corp Development | 152,379 | 0.03% | May 27, 2026 |
| Scott B. Ullem | CVP, Chief Financial Officer | 313,058 | 0.05% | May 11, 2026 |
| Larry L. Wood | Global President TAVR & Surg | 207,049 | 0.04% | Aug 18, 2025 |
| Leslie C. Davis | Director | 9,834 | 0.00% | May 8, 2026 |
| Nicholas J. Valeriani | Director | 84,423 | 0.01% | May 8, 2026 |
| Kieran Gallahue | Director | 82,907 | 0.01% | May 8, 2026 |
| Steven R. Loranger | Director | 83,305 | 0.01% | May 8, 2026 |
| Paul A. Laviolette | Director | 17,552 | 0.00% | May 8, 2026 |
| David T. Feinberg | Director | 9,087 | 0.00% | May 8, 2026 |
| Heisz Leslie Stone | Director | 34,199 | 0.01% | May 8, 2026 |
| Ramona Sequeira | Director | 20,855 | 0.00% | May 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Wayne Markowitz CVP, JAPAC | Sep 14, 2026 | Tax withholding | −568 | $84.37 | $47.92K | 19,371 |
| Andrew M. Dahl SVP, Corporate Controller | Sep 13, 2026 | Tax withholding | −253 | $84.37 | $21.35K | 14,615 |
| Wayne Markowitz CVP, JAPAC | Sep 11, 2026 | Tax withholding | −355 | $86.77 | $30.80K | 19,939 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Sep 11, 2026 | Tax withholding | −398 | $86.77 | $34.53K | 43,926 |
| Daniel J. Lippis CVP, TAVR | Sep 11, 2026 | Sale(10b5-1 plan) | −619 | $87.51 | $54.17K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Sep 11, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Andrew M. Dahl SVP, Corporate Controller | Aug 31, 2026 | Sale | −544 | $91.06 | $49.54K | 14,868 |
| Annette Bruls CVP, EMEACLA | Aug 28, 2026 | Sale | −2,644 | $89.98 | $237.91K | 17,984 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Sale | −1,154 | $91.76 | $105.89K | 74,970 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Sale | −30,646 | $90.99 | $2.79M | 44,324 |
| Daveen Chopra CVP, TMTT, Surgical & IHFM | Aug 26, 2026 | Option exercise | +31,800 | $72.68 | $2.31M | 76,124 |
| Wayne Markowitz CVP, JAPAC | Aug 26, 2026 | Sale | −1,240 | $91.47 | $113.42K | 20,294 |
| Daniel J. Lippis CVP, TAVR | Aug 11, 2026 | Sale(10b5-1 plan) | −619 | $92.03 | $56.97K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Aug 11, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Wayne Markowitz CVP, JAPAC | Jul 30, 2026 | Sale | −146.31 | $86.03 | $12.59K | 21,534 |
| Wayne Markowitz CVP, JAPAC | Jul 28, 2026 | Sale | −9,628 | $85.06 | $818.96K | 21,680 |
| Wayne Markowitz CVP, JAPAC | Jul 28, 2026 | Option exercise | +9,628 | $74.02 | $712.66K | 31,308 |
| Bernard J. Zovighian CEO, Director | Jul 27, 2026 | Gift | +319.65 | – | – | 11,836 |
| Bernard J. Zovighian CEO, Director | Jul 27, 2026 | Sale | −2,920.55 | $83.93 | $245.12K | 8,916 |
| Bernard J. Zovighian CEO, Director | Jul 27, 2026 | Gift | −319.65 | – | – | 98,845 |
| Annette Bruls CVP, EMEACLA | Jul 11, 2026 | Tax withholding | −109 | $92.21 | $10.05K | 20,628 |
| Daniel J. Lippis CVP, TAVR | Jul 10, 2026 | Option exercise | +619 | $72.68 | $44.99K | 40,653 |
| Daniel J. Lippis CVP, TAVR | Jul 10, 2026 | Sale(10b5-1 plan) | −619 | $91.70 | $56.76K | 40,034 |
| Theodora Mistras CVP, Chief Financial Officer | Jul 9, 2026 | Award | +87,595 | – | – | 87,595 |
| Theodora Mistras CVP, Chief Financial Officer | Jul 9, 2026 | Award | +12,325 | – | – | 99,920 |
| Daniel J. Lippis CVP, TAVR | Jul 7, 2026 | Tax withholding | −377 | $95.18 | $35.88K | 40,034 |
| Daniel J. Lippis CVP, TAVR | Jun 30, 2026 | Option exercise | +619 | $72.68 | $44.99K | 41,030 |
| Daniel J. Lippis CVP, TAVR | Jun 30, 2026 | Sale(10b5-1 plan) | −619 | $91.40 | $56.58K | 40,411 |
| Bernard J. Zovighian CEO, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −523 | $87.92 | $45.98K | 11,517 |
| Andrew M. Dahl SVP, Corporate Controller | May 29, 2026 | Sale | −567.53 | $86.08 | $48.85K | 15,334 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 27, 2026 | Sale | −23,145 | $86.42 | $2.00M | 98,611 |
| Daveen Chopra CVP, TMTT & Surgical | May 22, 2026 | Sale | −1,500 | $84.60 | $126.90K | 44,324 |
| Daniel J. Lippis CVP, TAVR | May 18, 2026 | Sale(10b5-1 plan) | −620 | $81.14 | $50.31K | 40,411 |
| Daniel J. Lippis CVP, TAVR | May 18, 2026 | Option exercise | +620 | $72.68 | $45.06K | 41,031 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 15, 2026 | Sale | −9,968 | $82.07 | $818.07K | 22,798 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 15, 2026 | Sale | −8,000 | $81.82 | $654.56K | 30,970 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Gift | −26,640 | – | – | 99,165 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Gift | +26,640 | – | – | 48,391 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −845 | $78.40 | $66.25K | 47,546 |
| Bernard J. Zovighian CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −35,506 | $77.92 | $2.77M | 12,040 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 11, 2026 | Tax withholding | −7,469 | $79.96 | $597.22K | 32,766 |
| Donald E. Bobo Jr CVP,Strategy/Corp Development | May 11, 2026 | Option exercise | +13,457 | – | – | 40,235 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Tax withholding | −26,198 | $79.96 | $2.09M | 125,805 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Option exercise | +47,207 | – | – | 157,492 |
| Daveen Chopra CVP, TMTT & Surgical | May 11, 2026 | Tax withholding | −7,538 | $79.96 | $602.74K | 45,824 |
| Daveen Chopra CVP, TMTT & Surgical | May 11, 2026 | Option exercise | +13,583 | – | – | 53,362 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Gift | +5,489 | – | – | 21,751 |
| Bernard J. Zovighian CEO, Director | May 11, 2026 | Gift | −5,489 | – | – | 104,796 |
| Wayne Markowitz CVP, JAPAC | May 11, 2026 | Sale | −593 | $79.73 | $47.28K | 21,680 |
| Daniel J. Lippis CVP, TAVR | May 11, 2026 | Tax withholding | −362 | $79.96 | $28.95K | 40,411 |
| Scott B. Ullem CVP, Chief Financial Officer | May 11, 2026 | Tax withholding | −11,004 | $79.96 | $879.88K | 46,740 |
| Scott B. Ullem CVP, Chief Financial Officer | May 11, 2026 | Option exercise | +19,830 | – | – | 57,744 |
| Bernard J. Zovighian CEO, Director | May 8, 2026 | Gift | +4,222 | – | – | 16,262 |
| Bernard J. Zovighian CEO, Director | May 8, 2026 | Tax withholding | −5,398 | $82.76 | $446.74K | 110,285 |
| Bernard J. Zovighian CEO, Director | May 8, 2026 | Gift | −4,222 | – | – | 115,683 |
| Wayne Markowitz CVP, JAPAC | May 8, 2026 | Tax withholding | −226 | $82.76 | $18.70K | 22,273 |
| Daveen Chopra CVP, TMTT & Surgical | May 8, 2026 | Tax withholding | −1,141 | $82.76 | $94.43K | 39,779 |
| Daniel J. Lippis CVP, TAVR | May 8, 2026 | Tax withholding | −450 | $82.76 | $37.24K | 40,773 |
| Scott B. Ullem CVP, Chief Financial Officer | May 8, 2026 | Tax withholding | −1,661 | $82.76 | $137.46K | 37,914 |
| Heisz Leslie Stone Director | May 8, 2026 | Award | +3,251 | – | – | 34,199 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Andrew M. Dahl Officer | Aug 31, 2026 | 544 | $49.53K | Aug 31, 2026 | Restricted Stock Lapse |
| Annette Bruls Officer | Aug 28, 2026 | 2,644 | $237.91K | Aug 28, 2026 | Restricted Stock Lapse |
| Daveen Chopra Officer | Aug 26, 2026 | 31,800 | $2.89M | Aug 26, 2026 | Employee Stock Option Exercise |
| Wayne Markowitz Officer | Aug 26, 2026 | 1,240 | $113.42K | Aug 26, 2026 | Restricted Stock Lapse |
| Daniel J. Lippis Officer | Aug 11, 2026 | 1,857 | $170.90K | Aug 11, 2026 | Employee Stock Option Exercise - See Remarks |
| Scott B. Ullem Former Affiliate | Jul 30, 2026 | 50,000 | $4.63M | Jul 30, 2026 | RSU / PSU - See Remarks |
| Wayne Markowitz Officer | Jul 30, 2026 | 147 | $12.59K | Jul 30, 2026 | ESPP - See Remarks |
| Wayne Markowitz Officer | Jul 28, 2026 | 9,628 | $818.96K | Jul 28, 2026 | Employee Stock Option Exercise |
| Bernard J. Zovighian Officer, Director | Jul 27, 2026 | 2,921 | $245.13K | Jul 27, 2026 | Exercise & Hold |
| Andrew M. Dahl Officer | May 29, 2026 | 568 | $48.85K | May 29, 2026 | Restricted Stock Lapse |
| Scott B. Ullem Former Affiliate | May 29, 2026 | 64,152 | $5.56M | May 29, 2026 | RSU / PSU - See Remarks |
| Jr Family Trust Bobo Officer | May 27, 2026 | 23,145 | $2.00M | May 27, 2026 | Restricted stock vesting under a registered plan |
| Daveen Chopra Officer | May 22, 2026 | 1,500 | $126.91K | May 22, 2026 | Performance Stock Lapse |
| Daniel J. Lippis Officer | May 18, 2026 | 1,858 | $150.76K | May 18, 2026 | Employee Stock Option Exercise - See Remarks |
| Donald E. Bobo Jr Officer | May 15, 2026 | 9,968 | $818.11K | May 15, 2026 | RSU / PSU - See Remarks |